Compare TransMedics Group Inc (TMDX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Valero Energy Corporation — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Valero Energy Corporation trades at $313.64 (market cap $93.03B). The key difference: Valero Energy Corporation is far larger — about 36.6× TransMedics Group Inc's market cap, and Valero Energy Corporation pays a 1.53% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VLO | |
|---|---|---|
Market Cap | $2.54B | $93.03B |
Sector | Technology | Energy |
52-Week High | $150.42 | $313.31 |
52-Week Low | $61.99 | $131.77 |
Enterprise Value | $2.94B | $98.79B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Valero Energy (VLO) trades at $314.80, up 1.66% today and near its 52-week high, with a bullish technical outlook supported by strong moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 expected at $10.13 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 3.37%, while valuation ratios like P/E of 22.89 and P/S of 0.77 reflect moderate pricing relative to peers. Recent news highlights robust refining margins and dividend declarations of $1.20 per share.
VLO's outlook is positive due to elevated crack spreads and strong fuel demand, though revenue declines pose a risk. Analyst consensus is bullish with a $285.38 price target, but high RSI levels suggest potential near-term pullbacks. Investment appeal lies in earnings momentum and shareholder returns, balanced against exposure to volatile energy markets and refining margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
